Vitality Re X

For the second-quarter of 2020, the medical benefit claims ratio reported by CVS-owned health insurer Aetna dropped even further below levels where its Vitality Re series of health insurance-linked securities (ILS) transactions could be triggered.

Despite the impacts of the Covid-19 coronavirus pandemic, the medical benefit claims ratio reported by insurer Aetna for the first-quarter of 2020 has remained well-below the levels where its Vitality Re series of health insurance-linked securities (ILS) transactions could be triggered, we can report.

The secondary market prices for the Vitality Re series of health insurance-linked securities (ILS) transactions have all been discounted on the potential for the ongoing Covid-19 coronavirus pandemic to drive an elevated level of medical benefit claims through to insurer and sponsor Aetna.

The Vitality Re series of health insurance-linked securities (ILS) transactions, which provide reinsurance protection to health insurer Aetna, are exposed to potential triggering by the coronavirus pandemic should it result in “severe morbidity stress”, rating agency S&P has said.

Aetna, the health, medical and benefits insurance arm of CVS Health, has successfully completed its latest and tenth trip to the catastrophe bond and insurance-linked securities (ILS) market for collateralized reinsurance, with its $200 million Vitality Re X Ltd. (Series 2019) deal.

Health insurance giant Aetna will be delighted with the response from ILS investors to its latest and tenth health or medical benefit risk ILS transaction, the $200 million Vitality Re X Ltd. (Series 2019) deal, as pricing falls to the bottom of initial guidance.

Health insurance giant Aetna is returning to the capital markets and insurance-linked securities with what will be its tenth health or medical benefit risk ILS transaction, a $200 million Vitality Re X Ltd. (Series 2019) deal.